Nautilus Biotechnology, Inc.
Close on Oct 19, 2026
- Market cap
- $334.37M
- P/E (TTM)
- –
- Dividend yield
- –
About Nautilus Biotechnology
Laboratory Analytical Instruments, SIC 3826
Nautilus Biotechnology is a development-stage life sciences company that develops platform technology for single-molecule proteomic analysis. The company's core offering is the Nautilus Voyager platform, an end-to-end system that combines nanofabricated protein arrays, instruments, consumables, and machine-learning software to measure protein abundance and functional variants using its iterative mapping technique. Its applications encompass broadscale proteome profiling and targeted proteoform analysis, alongside fee-for-service proteomics analysis offerings. Nautilus serves researchers at biopharmaceutical companies, academic institutions, and research organizations.
The text does not state the company's corporate headquarters, but notes that it maintains an internal facility in San Carlos, California, alongside outsourced contract manufacturing operations. More than one-third of its workforce holds doctoral degrees. The company maintains research partnerships with academic and scientific organizations located in the United States and Qatar.
Summary of the business section of Nautilus Biotechnology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Nautilus Biotechnology, Inc.
- Headquarters
- Seattle, WA
- Address
- 2701 Eastlake Ave East 98102
- Phone
- (206) 333-2001
- Website
- nautilus.bio
- Employees
- 130, Dec 31, 2025
- Industry
- Laboratory Analytical Instruments
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, San Jose, California
Stock & identifiers
- Ticker
- NAUT
- Exchange
- Nasdaq
- IPO date
- Aug 10, 2020
- Shares outstanding
- 127M, Jul 24, 2026
- Public float
- $35.80M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1808805
- CUSIP
- 63909J108
- ISIN
- US63909J1088
- EIN
- 98-1541723
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sujal M. Patel | CEO, President, and Secretary, Director | 17,461,232 |
| Parag Mallick | Chief Scientist, Director | 20,493,392 |
| Subramanian Sankar | Senior VP, Product Development | 91,250 |
| Gwen E. Weld | Chief People Officer | 30,000 |
| Kentaro Suzuki | Chief Marketing Officer | 4,000 |
| Anna Mowry | CFO and Treasurer | 83,000 |
| Matthew B. Murphy | General Counsel | 75,390 |
| Nicholas A. Nelson | CBO & Senior VP, Bus. Dev. | – |
| Matthew S. McIlwain | Director | 6,479,845 |
| Karen Akinsanya | Director | – |
| Farzad Nazem | Director | 1,888,146 |
| Epperly Melissa B, | Director | – |
| Matthew L. Posard | Director | 140,000 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 130 employees, all based in the United States, over one-third of whom hold doctorate degrees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 2, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 10, 2021 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jun 10, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 8, 2021 | Name change | Name changed from ARYA Sciences Acquisition Corp III to Nautilus Biotechnology, Inc. |
| Mar 26, 2021 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Aug 10, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 6, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |